Financial Analysis: Brainchip (OTCMKTS:BRCHF) & Mirion Technologies (NYSE:MIR)

Brainchip (OTCMKTS:BRCHF) and Mirion Technologies (NYSE:MIR) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Volatility and Risk

Brainchip has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Mirion Technologies has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Brainchip and Mirion Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainchip	0	0	0	0	0.00
Mirion Technologies	0	2	7	0	2.78

Mirion Technologies has a consensus target price of $28.38, suggesting a potential upside of 33.37%. Given Mirion Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Mirion Technologies is more favorable than Brainchip.

Earnings & Valuation

This table compares Brainchip and Mirion Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainchip	$400,000.00	N/A	N/A	N/A	N/A
Mirion Technologies	$925.40 million	5.83	$28.80 million	$0.11	193.41

Mirion Technologies has higher revenue and earnings than Brainchip.

Institutional and Insider Ownership

78.5% of Mirion Technologies shares are held by institutional investors. 6.3% of Mirion Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Brainchip and Mirion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brainchip	N/A	N/A	N/A
Mirion Technologies	3.11%	6.97%	3.85%

Summary

Mirion Technologies beats Brainchip on 9 of the 10 factors compared between the two stocks.

About Brainchip

BrainChip Holdings Ltd develops software and hardware accelerated solutions for artificial intelligence and machine learning applications in North America, Oceania, Europe, the Middle East, and Asia. The company primarily focuses on development of Akida Neuromorphic Processor to provide ultra-low power and fast AI Edge Network for vision, audio, olfactory, and smart transducer applications. It also offers Akida IP, a neural processor; MetaTF, which is used for creation, training, and testing of neutral network; Akida enablement platforms, including Akida PCI, Edge AI box, and development kit and shuttle PC and raspberry Pi; AKD1000, a reference chip as a hardware accelerator; and 2nd generation akidaTM expands the benefits of event-based, neuromorphic processing for network models. In addition, the company provides MetaTF ML framework python packages, which includes Akida python package, an interface to the BrainChip Akida Neuromorphic System-on-Chip; CNN2SNN tool provides means to convert convolutional neural networks; and the Akida model zoo, a pre-created network models built with the Akida sequential API and the CNN2SNN tool using quantized Keras models. Its products are used for original equipment manufacturer, end users, and system integrators based on artificial neural networks. The company was formerly known as Aziana Limited. BrainChip Holdings Ltd was incorporated in 2011 and is based in Sydney, Australia.

About Mirion Technologies

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, South Korea, and Japan. It operates through two segments, Medical and Technologies. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Technologies segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. The company was incorporated in 2005 and is headquartered in Atlanta, Georgia.